U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

erlotinib response - Efficacy

MedGen UID:
1001787
•Concept ID:
CN322731
•
Sign or Symptom

Professional guidelines

PubMed

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.
Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M, de Marinis F
Pharmacol Res 2017 Mar;117:406-415. Epub 2017 Jan 12 doi: 10.1016/j.phrs.2017.01.003. PMID: 28089942
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
Passaro A, Cortesi E, de Marinis F
Expert Rev Anticancer Ther 2011 Oct;11(10):1587-97. doi: 10.1586/era.11.120. PMID: 21999132
Pharmacogenetic application in personalized cancer treatment.
Kristyanto H, Utomo AR
Acta Med Indones 2010 Apr;42(2):109-15. PMID: 20513938

Recent clinical studies

Etiology

Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W, Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, Geng X, Chen J, An H, Yuan Y, Xu T, Chen D, Lin D, Xu L, Huang K, Peng L, Yu Y, Tai S, Qi H, Luo K, Kang X, Wang H, Huang Y, Zhang J, Xue W
Eur Urol 2023 Feb;83(2):163-172. Epub 2022 Jun 15 doi: 10.1016/j.eururo.2022.05.029. PMID: 35715365
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K
Jpn J Clin Oncol 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179. PMID: 30508196Free PMC Article
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C
Lancet Oncol 2011 Aug;12(8):735-42. Epub 2011 Jul 23 doi: 10.1016/S1470-2045(11)70184-X. PMID: 21783417

Diagnosis

Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib.
Ge W, Wang Y, Quan M, Mao T, Bischof EY, Xu H, Zhang X, Li S, Yue M, Ma J, Yang H, Wang L, Yu Z, Wang L, Cui J
Mol Cancer 2024 Mar 8;23(1):48. doi: 10.1186/s12943-024-01965-5. PMID: 38459558Free PMC Article
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, Chu Q, Xia S, Zhang P, Zhang L, Chen Y, Zhang L
Radiother Oncol 2023 Jul;184:109681. Epub 2023 Apr 25 doi: 10.1016/j.radonc.2023.109681. PMID: 37105304
Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
Li X, Wang F, Jia H, Lian Z, Ren K, Yuan Z, Wang P, Zhao L
Future Oncol 2022 Sep;18(27):3055-3065. Epub 2022 Aug 10 doi: 10.2217/fon-2022-0491. PMID: 35947522
Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials.
Zhang J, Zong Y, Xu GZ, Xing K
Saudi Med J 2016 Nov;37(11):1184-1190. doi: 10.15537/smj.2016.11.16267. PMID: 27761555Free PMC Article
Adverse drug reactions in dermatology.
Ferner RE
Clin Exp Dermatol 2015 Mar;40(2):105-9; quiz 109-10. Epub 2015 Jan 27 doi: 10.1111/ced.12572. PMID: 25622648

Therapy

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M
Lancet Oncol 2019 May;20(5):625-635. Epub 2019 Apr 8 doi: 10.1016/S1470-2045(19)30035-X. PMID: 30975627
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C
Lancet Oncol 2011 Aug;12(8):735-42. Epub 2011 Jul 23 doi: 10.1016/S1470-2045(11)70184-X. PMID: 21783417
Erlotinib.
Steins M, Thomas M, Geissler M
Recent Results Cancer Res 2010;184:21-31. doi: 10.1007/978-3-642-01222-8_2. PMID: 20072828

Prognosis

Erlotinib.
Steins M, Thomas M, Geißler M
Recent Results Cancer Res 2018;211:1-17. doi: 10.1007/978-3-319-91442-8_1. PMID: 30069756
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Erlotinib.
Steins M, Thomas M, Geissler M
Recent Results Cancer Res 2014;201:109-23. doi: 10.1007/978-3-642-54490-3_6. PMID: 24756788
Erlotinib.
Steins M, Thomas M, Geissler M
Recent Results Cancer Res 2010;184:21-31. doi: 10.1007/978-3-642-01222-8_2. PMID: 20072828
Targeted cancer therapies.
Blay JY, Le Cesne A, Alberti L, Ray-Coquart I
Bull Cancer 2005 Feb;92(2):E13-8. PMID: 15749638

Clinical prediction guides

EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, Chu Q, Xia S, Zhang P, Zhang L, Chen Y, Zhang L
Radiother Oncol 2023 Jul;184:109681. Epub 2023 Apr 25 doi: 10.1016/j.radonc.2023.109681. PMID: 37105304
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K
J Clin Oncol 2023 Feb 10;41(5):1105-1115. Epub 2022 Oct 26 doi: 10.1200/JCO.22.00739. PMID: 36288547Free PMC Article
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W, Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, Geng X, Chen J, An H, Yuan Y, Xu T, Chen D, Lin D, Xu L, Huang K, Peng L, Yu Y, Tai S, Qi H, Luo K, Kang X, Wang H, Huang Y, Zhang J, Xue W
Eur Urol 2023 Feb;83(2):163-172. Epub 2022 Jun 15 doi: 10.1016/j.eururo.2022.05.029. PMID: 35715365
Erlotinib.
Steins M, Thomas M, Geißler M
Recent Results Cancer Res 2018;211:1-17. doi: 10.1007/978-3-319-91442-8_1. PMID: 30069756
Erlotinib.
Steins M, Thomas M, Geissler M
Recent Results Cancer Res 2010;184:21-31. doi: 10.1007/978-3-642-01222-8_2. PMID: 20072828

Recent systematic reviews

Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
Li X, Wang F, Jia H, Lian Z, Ren K, Yuan Z, Wang P, Zhao L
Future Oncol 2022 Sep;18(27):3055-3065. Epub 2022 Aug 10 doi: 10.2217/fon-2022-0491. PMID: 35947522
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J
BMJ 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460. PMID: 31591158Free PMC Article
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH
Drug Des Devel Ther 2016;10:1961-72. Epub 2016 Jun 13 doi: 10.2147/DDDT.S105442. PMID: 27358556Free PMC Article
The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis.
Ma H, Tian X, Zeng XT, Zhang Y, Wang Y, Wang F, Zhou JG
Medicine (Baltimore) 2016 Jan;95(2):e2495. doi: 10.1097/MD.0000000000002495. PMID: 26765461Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...